- Future Students
- DVM degree program
- Graduate Programs
- Request information
- Contacts, Map, and Directions
- Current Students
- Faculty & Staff
Pre- and post-transplant anti-myosin and anti-heat shock protein antibodies and cardiac transplant outcome.
|Title||Pre- and post-transplant anti-myosin and anti-heat shock protein antibodies and cardiac transplant outcome.|
|Publication Type||Journal Article|
|Year of Publication||2004|
|Authors||Morgun A, Shulzhenko N, Unterkircher CS, Diniz RVZ, Pereira AB, Silva MS, Nishida SK, Almeida DR, Carvalho ACC, Franco M, Souza MM, Gerbase-DeLima M|
|Journal||The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation|
|Date Published||2004 Feb|
|Keywords||Adult, Autoantibodies, Cardiac Myosins, Cardiomyopathy, Dilated, Case-Control Studies, Chagas Cardiomyopathy, Enzyme-Linked Immunosorbent Assay, Female, Graft Rejection, Heart Transplantation, Heat-Shock Proteins, Humans, Immunoglobulin G, Male, Myocardial Ischemia, Time Factors|
BACKGROUND: The purpose this study was to investigate the relationship of anti-myosin and anti-heat shock protein immunoglobulin G (IgG) serum antibodies to the original heart disease of cardiac transplant recipients, and also to rejection and patient survival after cardiac transplantation.
METHODS: Anti-myosin and anti-heat shock protein (anti-hsp) IgG antibodies were evaluated in pre-transplant sera from 41 adult cardiac allograft recipients and in sequential post-transplant serum samples from 11 recipients, collected at the time of routine endomyocardial biopsies during the first 6 months after transplantation. In addition, the levels of these antibodies were determined from the sera of 28 healthy blood donors.
RESULTS: Higher anti-myosin antibody levels were observed in pre-transplant sera than in sera from normal controls. Moreover, patients with chronic Chagas heart disease showed higher anti-myosin levels than patients with ischemic heart disease, and also higher levels, although not statistically significant, than patients with dilated cardiomyopathy. Higher anti-hsp levels were also observed in patients compared with healthy controls, but no significant differences were detected among the different types of heart diseases. Higher pre-transplant anti-myosin, but not anti-hsp, levels were associated with lower 2-year post-transplant survival. In the post-transplant period, higher anti-myosin IgG levels were detected in sera collected during acute rejection than in sera collected during the rejection-free period, whereas anti-hsp IgG levels showed no difference between these periods.
CONCLUSIONS: The present findings are of interest for post-transplant management and, in addition, suggest a pathogenic role for anti-myosin antibodies in cardiac transplant rejection, as has been proposed in experimental models of cardiac transplantation.
|Alternate Journal||J. Heart Lung Transplant.|